Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Down0.10% Nasdaq Up0.23%

Receptos, Inc. (RCPT)

-NasdaqGS
35.99 Up 0.96(2.74%) Apr 17, 4:00PM EDT
|After Hours : 35.99 0.00 (0.00%) Apr 17, 4:29PM EDT
Get the big picture on all your investments.
ProfileGet Profile for:
Receptos, Inc.
10835 Road to the Cure
Suite 205
San Diego, CA 92121
United States - Map
Phone: 858-652-5700
Fax: 858-587-2659
Website: http://www.receptos.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:41

Business Summary 

Receptos, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics for immune disorders. Its lead product includes RPC1063, an oral sphingosine 1-phosphate 1 receptor modulator that is in Phase II portion of Phase II/III studies for the treatment of relapsing multiple sclerosis; and is in Phase II studies to treat ulcerative colitis. The company is also developing RPC4046, a monoclonal antibody, which is in Phase II studies for the treatment of eosinophilic esophagitis, an allergic/immune-mediated disorder. In addition, it is involved in a research program for glucagon-like peptide-1 receptor small molecule positive allosteric modulators that are in preclinical studies for the treatment of Type 2 diabetes. The company was formerly known as Receptor Pharmaceuticals, Inc. and changed its name to Receptos, Inc. in May 2009. Receptos, Inc. was founded in 2008 and is headquartered in San Diego, California.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Receptos, Inc.

Key Executives 
 PayExercised
Dr. William H. Rastetter Ph.D., 66
Co-Founder, Exec. Chairman, Chairman of Nominating & Corp. Governance Committee, Member of Audit Committee and Member of Compensation Committee
52.00KN/A
Mr. Faheem Hasnain , 56
Chief Exec. Officer, Pres and Director
456.00K0.00
Ms. Kristina Burow , 41
Co-Founder, Director, Chairman of Compensation Committee and Member of Nominating & Corp. Governance Committee
34.00KN/A
Mr. Graham K. Cooper , 44
Chief Financial Officer
278.00K0.00
Dr. Sheila Gujrathi M.D., 44
Chief Medical officer
371.00K0.00
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders